Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)
- PMID: 24113837
- PMCID: PMC3880487
- DOI: 10.1007/s11657-013-0136-1
Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)
Abstract
This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27).
Introduction: Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for affected patients and substantial costs to society. The aim of this report was to characterize the burden of osteoporosis in the EU27 in 2010 and beyond.
Methods: The literature on fracture incidence and costs of fractures in the EU27 was reviewed and incorporated into a model estimating the clinical and economic burden of osteoporotic fractures in 2010.
Results: Twenty-two million women and 5.5 million men were estimated to have osteoporosis; and 3.5 million new fragility fractures were sustained, comprising 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures (i.e. fractures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum and other femoral fractures). The economic burden of incident and prior fragility fractures was estimated at <euro> 37 billion. Incident fractures represented 66 % of this cost, long-term fracture care 29 % and pharmacological prevention 5 %. Previous and incident fractures also accounted for 1,180,000 quality-adjusted life years lost during 2010. The costs are expected to increase by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining.
Conclusions: In spite of the high social and economic cost of osteoporosis, a substantial treatment gap and projected increase of the economic burden driven by the aging populations, the use of pharmacological interventions to prevent fractures has decreased in recent years, suggesting that a change in healthcare policy is warranted.
Similar articles
-
Osteoporosis in the European Union: a compendium of country-specific reports.Arch Osteoporos. 2013;8(1):137. doi: 10.1007/s11657-013-0137-0. Epub 2013 Oct 11. Arch Osteoporos. 2013. PMID: 24113838 Free PMC article. Review.
-
Epidemiology and economic burden of osteoporosis in Switzerland.Arch Osteoporos. 2014;9:187. doi: 10.1007/s11657-014-0187-y. Epub 2014 Jun 27. Arch Osteoporos. 2014. PMID: 24970672 Review.
-
Current and future economic burden of osteoporosis in New Zealand.Appl Health Econ Health Policy. 2011 Mar 1;9(2):111-23. doi: 10.2165/11531500-000000000-00000. Appl Health Econ Health Policy. 2011. PMID: 21271750
-
Fragility fractures in Europe: burden, management and opportunities.Arch Osteoporos. 2020 Apr 19;15(1):59. doi: 10.1007/s11657-020-0706-y. Arch Osteoporos. 2020. PMID: 32306163 Free PMC article.
-
SCOPE: a scorecard for osteoporosis in Europe.Arch Osteoporos. 2013;8(1):144. doi: 10.1007/s11657-013-0144-1. Epub 2013 Sep 13. Arch Osteoporos. 2013. PMID: 24030479 Free PMC article.
Cited by
-
The role of sarcopenia in the risk of osteoporotic hip fracture.Clin Rheumatol. 2015 Oct;34(10):1673-80. doi: 10.1007/s10067-015-2943-9. Epub 2015 Apr 26. Clin Rheumatol. 2015. PMID: 25912213 Review.
-
Evaluation of costs, osteoporosis treatment, and re-fractures in German collaborative orthogeriatric care after fragility fractures.Osteoporos Int. 2024 Jan;35(1):81-91. doi: 10.1007/s00198-023-06965-7. Epub 2023 Nov 9. Osteoporos Int. 2024. PMID: 37940697 Free PMC article.
-
Current status and distribution of hip fractures among older adults in China.Osteoporos Int. 2021 Sep;32(9):1785-1793. doi: 10.1007/s00198-021-05849-y. Epub 2021 Mar 2. Osteoporos Int. 2021. PMID: 33655399
-
Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.J Comp Eff Res. 2024 Apr;13(4):e230090. doi: 10.57264/cer-2023-0090. Epub 2024 Feb 6. J Comp Eff Res. 2024. PMID: 38317634 Free PMC article.
-
Pre-fracture individual characteristics associated with high total health care costs after hip fracture.Osteoporos Int. 2017 Mar;28(3):889-899. doi: 10.1007/s00198-016-3803-4. Epub 2016 Oct 14. Osteoporos Int. 2017. PMID: 27743069 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous